News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
中生製藥(01177.HK)1類創新藥M701相關新藥上市申請獲受理
中生製藥(01177.HK)公布，附屬正大天晴聯合開發的國家1類創新藥M701「CD3/EpCAM雙特異性抗體」用於治療晚期上皮性惡性腫瘤導致的惡性腹水，已向國家藥品監督管理局藥品審評中心遞交新藥上市申請，並獲得受理。M701是國內首個自主開發的CD3/EpCAM雙特異性抗體，可同時靶向腫瘤細胞靶點EpCAM和免疫T細胞活化靶點CD3，通過雙靶結合橋連腫瘤細...
Reset
Send
The window will close in 5 seconds
中生製藥(01177.HK)1類創新藥M701相關新藥上市申請獲受理
Close
Recommend
20
Positive
28
Negative
7
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get Level 1 Real-Time Streaming!

中生製藥(01177.HK)  -0.130 (-2.249%)    Short selling $43.14M; Ratio 14.151%   公布，附屬正大天晴聯合開發的國家1類創新藥M701「CD3/EpCAM雙特異性抗體」用於治療晚期上皮性惡性腫瘤導致的惡性腹水，已向國家藥品監督管理局藥品審評中心遞交新藥上市申請，並獲得受理。

M701是國內首個自主開發的CD3/EpCAM雙特異性抗體，可同時靶向腫瘤細胞靶點EpCAM和免疫T細胞活化靶點CD3，通過雙靶結合橋連腫瘤細胞和免疫T細胞，從而激活T細胞對腫瘤細胞進行殺傷。(ha/a)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-05-13 16:25.)

Switch to Auto-Translated Version
AASTOCKS新聞
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.